The agreement with IBM clears Elekta to start offering the artificial intelligence technology alongside its oncology information system.

The deal will give Varian control of radioembolization technology to complement its existing portfolio of cancer-care devices.

The agreement sees Boston Scientific buy $90 million of Millipede stock and gain the right to acquire the rest of the business for up to $450 million.

J&J began assessing whether to sell subsidiaries that make glucose meters, insulin pumps and other pieces of diabetes equipment last year.

The initiative will provide certain UnitedHealth members with Dexcom’s CGM technology and personalized coaching to help manage their diabetes.

Illumina, the maker of DNA sequencers, unveiled its latest device with a price tag of just under $20,000.

TAI will use the cash to advance the cell-free DNA transplant monitoring technology that attracted United Therapeutics.

The partners will create a joint fund that invests in technologies globally and then seeks to accelerate their progress in China.